The AHA Guidelines and Scientific Statements Handbook

(vip2019) #1

The AHA Guidelines and Scientifi c Statements Handbook


objective testing, and no trial of medical therapy, or
who have 1 of the following:


a. Only a small area of myocardium at risk. (Level
of Evidence: C)
b. All lesions or the culprit lesion to be dilated with
morphology that conveys a low likelihood of success.
(Level of Evidence: C)
c. A high risk of procedure-related morbidity or
mortality. (Level of Evidence: C)
d. Insignifi cant disease (less than 50% coronary ste-
nosis). (Level of Evidence: C)
e. Signifi cant left main CAD and candidacy for
CABG. (Level of Evidence: C)


Patients with unstable angina (UA)/NSTEMI
Class I
1 An early invasive PCI strategy is indicated for
patients with UA/NSTEMI who have no serious
comorbidity‡ and who have coronary lesions ame-
nable to PCI and have characteristics that make
them candidates for invasive therapy (see Table 6.2


and Section 3.3 of the ACC/AHA 2007 UA/NSTEMI
guidelines) [4]. (Level of Evidence: A)
2 PCI (or CABG) is recommended for UA/NSTEMI
patients with 1- or 2-vessel CAD with or without
signifi cant proximal LAD CAD but with a large area
of viable myocardium and high-risk criteria on non-
invasive testing. (Level of Evidence: B)
3 PCI (or CABG) is recommended for UA/NSTEMI
patients with multivessel coronary disease with suit-
able coronary anatomy, with normal LV function,
and without diabetes mellitus. (Level of Evidence: A)
4 An intravenous platelet GP IIb/IIIa inhibitor is
useful in UA/NSTEMI patients undergoing PCI.
(Level of Evidence: A) See Section 3.2.3 of the 2007
ACC/AHA 2007 UA/NSTEMI guidelines and Table
6.2 [4].
5 An early invasive strategy (i.e., diagnostic angiog-
raphy with intent to perform revascularization) is
indicated in UA/NSTEMI patients who have refrac-
tory angina or hemodynamic or electrical instability
(without serious comorbidities or contraindications
to such procedures). (Level of Evidence: B)

Class IIa
1 PCI is reasonable for focal saphenous vein graft
lesions or multiple stenoses in UA/NSTEMI patients
who are undergoing medical therapy and who are

‡For example, severe hepatic, pulmonary, or renal failure, or
active/inoperable cancer. Clinical judgment is required in such
cases.


Table 6.2 Causes of UA/NSTEMI*


Thrombus or thromboembolism, usually arising on disrupted or eroded plaque



  • Occlusive thrombus, usually with collateral vessels†

  • Subtotally occlusive thrombus on pre-existing plaque

  • Distal microvascular thromboembolism from plaque-associated thrombus


Thromboembolism from plaque erosion



  • Non-plaque-associated coronary thromboembolism


Dynamic obstruction (coronary spasm‡ or vasoconstriction) of epicardial and/or microvascular vessels
Progressive mechanical obstruction to coronary fl ow
Coronary arterial infl ammation
Secondary UA
Coronary artery dissection§



  • These causes are not mutually exclusive; some patients have two or more causes.
    † From DeWood et al. [24].
    ‡ May occur on top of an atherosclerotic plaque, producing missed-etiology angina or UA/NSTEMI.
    § Rare.


Table modifi ed with permission from Braunwald [25].

Free download pdf